AccuStem Sciences, Inc. ACUT

Company Overview

AccuStem Sciences, Inc. (NASDAQ: ACUT) is a molecular diagnostics and precision oncology company focused on developing and commercializing genomic tests intended to support cancer treatment decisions. The company primarily operates within the oncology diagnostics and personalized medicine industries, with an emphasis on breast cancer prognostic testing and biomarker-driven clinical assessment. Public disclosures and investor materials identify the company’s principal commercial focus as improving risk stratification and treatment planning through gene-expression analysis and related molecular technologies.

The company’s principal revenue and strategic focus have centered on its breast cancer diagnostic platform, including the StemPrintER test, which is designed to help assess recurrence risk in patients with breast cancer. AccuStem evolved through a combination of biotechnology and diagnostic development activities and has operated through affiliated entities in both the United States and Europe. Its positioning in precision oncology is tied to proprietary genomic-analysis methodologies and its focus on clinically actionable diagnostic insights for oncologists and healthcare providers.